Source comparison
GHRP-2 Acetate vs MK-677: Research Application Comparison
Administration Route Subcutaneous injection, 2–3× daily Oral, once daily MK-677 offers significantly greater convenience; GHRP-2 requires injection experience and multiple daily administrations Half-Life ~30 minutes ~24 hours GHRP-2 allows precise temporal con
This comparison does not assign a generated winner or score.
- Administration Route
- Subcutaneous injection, 2–3× daily
- Oral, once daily
- MK-677 offers significantly greater convenience; GHRP-2 requires injection experience and multiple daily administrations
- Half-Life
- ~30 minutes
- ~24 hours
- GHRP-2 allows precise temporal control over GH pulses; MK-677 produces sustained elevation throughout the dosing interval
- GH Secretion Pattern
- Pulsatile (discrete peaks)
- Sustained elevation
- Pulsatile secretion with GHRP-2 more closely mimics endogenous rhythm; MK-677's constant elevation may be preferable or limiting depending on study design
- IGF-1 Increase
- 40–70% at 600mcg/day
- 60–90% at 25mg/day
- Comparable IGF-1 elevation at therapeutic doses; MK-677 produces slightly higher sustained levels
- Appetite Stimulation
- Mild, transient (60–90 min post-injection)
- Significant, sustained (entire dosing interval)
- MK-677's hunger stimulation is the primary tolerability concern in metabolic research; GHRP-2's effect is minimal
- Prolactin Effect
- No significant elevation
- 20–40% increase in some subjects
- Prolactin elevation with MK-677 may confound endocrine research; GHRP-2 does not affect prolactin
- Cost Per Day (Therapeutic Dose)
- $4.20–$6.60 (600mcg total)
- $2.25–$3.50 (25mg)
- MK-677 appears cheaper per dose but requires normalization for equivalent GH output; actual cost difference is 10–20% when matched for efficacy
- Storage Requirements
- Lyophilized: −20°C; reconstituted: 2–8°C
- Room temperature stable
- GHRP-2 requires cold-chain management; MK-677 simplifies storage and travel
- Synthesis Complexity
- Simple hexapeptide (solid-phase synthesis)
- Complex non-peptide small molecule
- GHRP-2 purity is more consistent across suppliers; MK-677 synthesis complexity increases contamination risk from non-verified sources